VEGFA and hypertensive disorder: In this regard, hypertension and its associated secondary events (i.e., myocardial infarction and stroke) may be the main complication in anti-AM therapy, which is indeed an adverse effect observed in patients undergoing VEGF-inhibiting treatments.